Department of Surgical Oncology and General Surgery, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, The First Affiliated Hospital of China Medical University, Urumqi, China.
Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Cell Mol Gastroenterol Hepatol. 2022;13(1):19-33. doi: 10.1016/j.jcmgh.2021.09.005. Epub 2021 Sep 20.
The stomach is a complex and physiologically necessary organ, yet large differences in physiology between mouse and human stomachs have impeded translation of physiological discoveries and drug screens performed using murine gastric tissues. Gastric cancer (GC) is a global health threat, with a high mortality rate and limited treatment options. The heterogeneous nature of GC makes it poorly suited for current "one size fits all" standard treatments. In this review, we discuss the rapidly evolving field of gastric organoids, with a focus on studies expanding cultures from primary human tissues and describing the benefits of mouse organoid models. We introduce the differing methods for culturing healthy gastric tissue from adult tissues or pluripotent stem cells, discuss the promise these systems have for preclinical drug screens, and highlight applications of organoids for precision medicine. Finally, we discuss the limitations of these models and look to the future to present potential ways gastric organoids will advance treatment options for patients with GC.
胃是一个复杂且在生理上必不可少的器官,但由于鼠类和人类的胃在生理学上存在很大差异,这阻碍了使用鼠类胃组织进行的生理发现和药物筛选的转化。胃癌(GC)是一个全球性的健康威胁,其死亡率高,治疗选择有限。GC 的异质性使其不适合当前的“一刀切”标准治疗。在这篇综述中,我们讨论了胃类器官这一快速发展的领域,重点介绍了从人原发性组织中扩展培养物的研究,并描述了鼠类类器官模型的优势。我们介绍了从成人组织或多能干细胞培养健康胃组织的不同方法,讨论了这些系统在临床前药物筛选中的应用前景,并强调了类器官在精准医学中的应用。最后,我们讨论了这些模型的局限性,并展望未来,提出胃类器官可能为 GC 患者的治疗选择带来的潜在进展。